Microtest to manufacture ImmusanT's celiac vaccine

Microtest Laboratories will manufacture Nexvax2 for a mid-stage trial of ImmusanT's vaccine as a treatment for celiac disease. ImmunsanT secured $20 million in venture captial funding from Vatera Healthcare Partners in December to advance clinical development of the vaccine. Article

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.